Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amantadine hydrochloride extended release - Adamas Pharmaceuticals

Next Previous
Search
Drug Profile

Amantadine hydrochloride extended release - Adamas Pharmaceuticals

Alternative Names: ALLAY-LID I; ALLAY-LID II; Amantadine HCl ER; Amantadine HCl Extended Release Tablets - RVL Pharmaceuticals; OS-320; Osmolex ER

Latest Information Update: 18 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Osmotica Pharmaceutical
  • Developer RVL Pharmaceuticals
  • Class Adamantanes; Antiparkinsonians; Antivirals; Organic bridged compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

  • 18 Mar 2024 Discontinued - Phase-III for Drug-induced dyskinesia in Spain, Canada, France, Germany (PO) (Supernus Pharmaceuticals pipeline, March 2024)
  • 31 Dec 2023 Withdrawn for Drug-induced dyskinesia in USA (PO)
  • 31 Dec 2023 Withdrawn for Parkinson's disease in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top